Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Omega-3s keep menopausal minds sharp?

NCT ID NCT07814300

Symptom relief Sponsor: St. Mary's University, Twickenham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are testing whether a daily algae-based omega-3 supplement can improve memory and thinking in perimenopausal and menopausal women aged 40 to 60. The study enrolls 42 women who take either the supplement or a placebo for 12 weeks. Scientists measure changes in verbal and working memory, plus menopausal symptoms, stress, and sleep, to see if omega-3s make a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an algae-based omega-3 supplement rich in DHA and EPA
What this could lead to
If it works, this could offer women a simple daily supplement to help protect memory and ease symptoms during menopause.
What could go wrong
This is a small, 12-week study of 42 women, so any memory benefit may be modest or fade. Supplements can also cause stomach upset or a fishy aftertaste.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Mar 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be female and aged between 40-60 years * Be experiencing perimenopause or menopause * Access to reliable internet connection and a device to complete online questionnaires and cognitive assessments * Be prepared to take a daily omega-3 supplement or placebo for 12 weeks * Be prepared to complete pre- and post- intervention testing and questionnaires * Speak English fluently to confirm they can complete cognitive tests to the best of their ability Exclusion Criteria: * Have diagnosed psychiatric or neurological condition (dementia, extreme depression, schizophrenia, bipolar disorder) which could affect cognitive function * Not currently be taking omega-3 supplements or regularly consuming fatty fish (1 portion per/week) * Be using hormone replacement therapy (HRT) * Have severe dietary restrictions * Have a history of stroke, cardiovascular disease or diabetes, as these conditions influence cognitive health * Are unable to commit to both baseline and follow-up tests after the 12-week period * Pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopause are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Menopause

Contacts and locations

Locations

  • St Mary's University

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.